The missense Thr211Pro mutation in the factor X activation peptide of a bleeding patient causes molecular defect in the clotting cascade

Summary

Factor X (FX) is a vitamin K-dependent coagulation zymogen, which upon activation to factor Xa assembles into the prothrombinase complex to activate prothrombin to thrombin. FX can be activated by either factor VIIa-tissue factor or factor IXa-factor VIIIa in extrinsic and intrinsic pathways, respectively. In this study, we identified a bleeding patient with moderate FX deficiency who exhibits a clotting defect only in the intrinsic pathway. Exome sequencing revealed that the patient carries a novel homozygous missense mutation that results in substitution of Thr211 with Pro in the activation peptide of FX. Thr211 is the site of an O-linked glycosylation in the activation peptide of FX. We postulated that the lack of this post-translational modification specifically impacts the activation of FX by intrinsic Xase, thereby impairing thrombin generation in the subject. To test this hypothesis, we expressed both wild-type FX and FX containing this mutation in mammalian cells and following the purification of the zymogens to homogeneity characterized their properties in both purified and plasma-based assay systems. Analysis of the results suggests that Thr211 to Pro substitution renders the FX mutant a poor substrate for both physiological activators, however, at physiological concentration of the substrate, the clotting defect manifest itself only in the intrinsic pathway, thus explaining the bleeding phenotype for the patient carrying this mutation.

Keywords

Coagulation factors - factor VIII - protein function / activity - thrombin - tissue factor / factor VII

^* Q. Ding and Y. Shen contributed equally to this work.

• References

• 1 Leytus SP, Foster DC, Kurachi K. et al. Gene for human factor X: A blood coagulation factor whose gene organisation is essentially identical with that of factor IX and protein C. Biochemistry 1986; 25: 5098-5102.
• 2 Mann KG, Nesheim ME, Church WR. et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
• 3 Stenflo J. Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors. Blood 1991; 78: 1637-1651.
• 4 Furie BC, Furie B. Coagulant protein Russell’s viper venom. Methods Enzymol 1976; 45: 191-205.
• 5 Bode W, Mayr I, Baumann U. et al. The refined 1.9 Å crystal structure of human a-thrombin: interaction with D-Phe-Pro-Arg chlorometheylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO J 1989; 08: 3467-3475.
• 6 Mann KG, Butenas S, Brummel K. The dynamics of thrombin generation. Arterioscler Thromb vasc Biol 2003; 23: 17-25.
• 7 Peyvandi F, Duga S, Akhavan S. et al. Rare coagulation deficiencies. Haemophilia 2002; 08: 308-321.
• 8 Karimi M, Menegatti M, Afrasiabi A. et al. Phenotype and genotype report on homozygous and heterozygous patients with congenital factor X deficiency. Haematologica 2008; 93: 934-938.
• 9 Herrmann FH, Auerswald G, Ruiz-Saez A. et al. For the Greifswald factor X deficiency study group. Factor X deficiency: clinical manifestation of 102 subjects from Europe and Latin America with mutations in the factor 10 gene. Haemophilia 2006; 12: 479-489.
• 10 Inoue K, Morita T. Identification of O-linked oligosaccharide chains in the activation peptides of blood coagulation factor X: The role of the carbohydrate moieties in the activation of factor X. Eur J Biochem 1993; 218: 153-163.
• 11 Sinha U, Wolf DL. Carbohydrate residues modulate the activation of coagulation factor X. J Biol Chem 1993; 268: 3048-3051.
• 12 Yang L, Manithody C, Rezaie AR. Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X. J Thromb Haemost 2009; 07: 1696-1702.
• 13 Wang WB, Fu QH, Zhou RF. et al. Molecular characterisation of two novel mutations causing factor X deficiency in a Chinese pedigree. Haemophilia 2005; 11: 31-37.
• 14 Carmichael H, Shen Y, Nguyen T. et al. Whole exome sequencing in a patient with uniparental disomy of chromosome 2 and a complex phenotype. Clin Genet. 2012 Nov 21. doi: 10.1111/cge.12064. [Epub ahead of print].
• 15 Smirnov MD, Esmon CT. Phosphatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-819.
• 16 Neuenschwander PF, Bianco-Fisher E, Rezaie AR. et al. Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry 1995; 34: 13988-13993.
• 17 Kittur FS, Manithody C, Rezaie AR. Role of the N-terminal epidermal growth factor-like domain of factor X/Xa. J Biol Chem 2004; 279: 24189-24196.
• 18 Manithody C, Yang L, Rezaie AR. Role of basic residues of the autolysis loop in the catalytic function of factor Xa. Biochemistry 2002; 41: 6780-6788.
• 19 Girolami A, Scarparo P, Scandellari R. et al. Congenital factor X deficiencies with a defect only or predominantly in the extrinsic or in the intrinsic system: a critical evaluation. Am J Hematol 2008; 83: 668-671.
• 20 Butenas S, van’t Veer C, Mann KG. “Normal” thrombin generation. Blood 1999; 94: 2169-2178.
• 21 Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
• 22 Sichler K, Banner DW, D’Arcy A. et al. Crystal structures of uninhibited factor VIIa link its cofactor and substrate-assisted activation to specific interactions. J Mol Biol 2002; 322: 591-603.
• 23 Neuenschwander PF. Exosite occupation by heparin enhances the reactivity of blood coagulation factor IXa. Biochemistry 2004; 43: 2978-2986.